NPPA: Ceiling price of scheduled formulations revised

The NPPA has revised/ increased the ceiling price of 883 scheduled formulations in compliance of the provisions of Drugs (Price Control) Order 2013.

The Authority conducted a meeting on 31.03.2020 noted with satisfaction that the supply disruption of APIs caused by COVID-19 outbreak is returning to normalcy and no unusual price fluctuations in price of inputs for medicines, amid COVID-19 outbreak has been reported. Thus, normal price revisions have been allowed.

The Wholesale Price Index increase has been based on the data published by Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India. Increase in ceiling price is based on Wholesale Price Index (WPI) is 1.88468 percent.

The revision in ceiling price of formulations also includes the revision of ceiling price of cardiac stents also.

The revised prices will be applicable from 1st April 2020 and the detail of revised prices is available on NPPA’s website

  • Related Posts

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Patients for Patient Safety Foundation (PFPSF) Partners with CAHO to RollOut an Excellence Program New Delhi: Thanks to some well-meaning organizations, patients are going to be lord of all they…

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting